Table 1 Patient characteristics prior to initial brain irradiation
Patient Characteristics | n =441 | n =37 |
|---|---|---|
Age (years) | Â | Â |
   Median | 55 | 48 |
Grade, primary tumor | Â | Â |
   1 | 13 (3%) | 1 (3%) |
   2 | 106 (24%) | 13 (35%) |
   3 | 315 (71%) | 22 (59%) |
   Unknown | 7(2%) | 1 (3%) |
Hormone receptor status, primary tumor | Â | Â |
   ER+ | 180 (41%) | 14 (38%) |
   ER- | 249 (56%) | 22 (60%) |
   Unknown | 12 (3%) | 1 (2%) |
HER2 status, primary tumor | Â | Â |
   Positive | 176 (40%) | 26 (70%) |
   Negative | 212 (48%) | 7 (19%) |
   Unknown | 53 (12%) | 4 (11%) |
KPS at first BM | Â | Â |
   < 70 | 170 (38%) | 10 (27%) |
   ≥ 70 | 271 (61%) | 27 (73%) |
ECOG at first BM | Â | Â |
   0-1 | 109 (25%) | 21 (57%) |
   2 | 186 (42%) | 13 (35%) |
   3-4 | 146 (33%) | 3 (8%) |
Number of lesions | Â | Â |
   1-3 | 190 (43%) | 21 (57%) |
   > 3 | 251 (57%) | 16 (43%) |
Primary status | Â | Â |
   Controlled | 305 (69%) | 28 (76%) |
   Uncontrolled | 135 (31%) | 9 (24%) |
Extracranial disease | Â | Â |
   Brain only | 97 (22%) | 19 (51%) |
   Bone + brain | 76 (17%) | 6 (16%) |
   Visceral + brain | 245 (56%) | 12 (32%) |
   Other | 23 (5%) | 0 (0%) |
RPA at first BM | Â | Â |
   1 | 55 (12%) | 11 (30%) |
   2 | 219 (50%) | 16 (43%) |
   3 | 167 (38%) | 10 (27%) |
Hormonal therapy at BM* | Â | Â |
   Yes | 100 (23%) | 14 (38%) |
   No | 341 (77%) | 23 (62%) |
Chemotherapy at BM* | Â | Â |
   Yes | 194 (44%) | 29 (78%) |
   No | 242 (55%) | 8 (22%) |
Trastuzumab at BM* | Â | Â |
   Yes | 136 (31%) | 21 (57%) |
   No | 305 (69%) | 16 (43%) |
Trastuzumab†|  |  |
   Yes | 157 (36%) | 25 (67%) |
   No | 284 (64%) | 12 (32%) |
Craniotomy | Â | Â |
   Yes | 87 (20%) | 16 (43%) |
   No | 354 (80%) | 21 (57%) |